Penumbra, Inc. (PEN)
After hours:
| Previous Close | 205.70 |
| Open | 207.31 |
| Bid | 0.00 x 800 |
| Ask | 244.89 x 800 |
| Day's Range | 204.12 - 209.01 |
| 52 Week Range | 180.93 - 348.67 |
| Volume | |
| Avg. Volume | 343,883 |
| Market Cap | 7.979B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | 88.48 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Penumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots
Penumbra, Inc. (NYSE: PEN), the world's largest thrombectomy company, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash™ 2.0, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary emboli (PE). Lightning Flash 2.0 features advanced Lightning Flash algorithms, designed for increased speed and sensitivity to thrombus and blood flow. These new advancements combined with Penumbra's novel cathet
- PR Newswire
Penumbra, Inc. Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024 at 4:30 PM Eastern Time. A press release with first quarter 2024 financial results will be issued after market close that day.
- PR Newswire
Penumbra, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2023.
